8-K: Dar Bioscience Closes Initial Regulation A Offering Tranche

Dar Bioscience, Inc. successfully completed the initial closing of its Regulation A offering, raising capital through the sale of Series A Convertible Preferred Stock and warrants.

Summary

• Dar Bioscience, Inc. completed the initial closing of its Regulation A offering on January 27, 2026, selling 5,090 Investor Units.
• Each Investor Unit, offered at $5.00, consists of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock.
• The Series A Preferred Stock has an initial stated value of $5.00 and is convertible into common stock at $2.50 per share, initially yielding two common shares per preferred share.
• Investor Warrants are exercisable at $4.00 per common share and expire 36 months from issuance.
• The company issued 152 Agent Unit Warrants to Digital Offering, LLC, representing 3% of the Investor Units sold, exercisable at $6.25 per Agent Unit and expiring on January 7, 2031.
• Digital Offering, LLC receives a 7.25% cash commission on units sold, a $25,000 consulting fee, and up to $85,000 in expense reimbursements.
• The offering is structured to allow multiple closings and will terminate by January 5, 2027, or earlier if the maximum amount is sold or at the company's discretion.
• Nasdaq Listing Rule 5635(d) limitations on conversion/issuance of common stock are not applicable, as the initial conversion price ($2.50) exceeded the common stock closing price ($1.90 on Jan 26, 2026) plus $0.125.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. While the initial capital raised is modest, the successful launch and initial closing of the Regulation A offering provide the company with a mechanism for ongoing capital infusion and avoids immediate Nasdaq stockholder approval requirements, which is favorable for operational flexibility.

Positives

• Successfully completed the initial closing of a Regulation A offering, providing capital to the company.
• The structure with Series A Preferred Stock and warrants offers flexibility in capital raising and potential for future common stock conversion.
• Avoidance of Nasdaq Listing Rule 5635(d) limitations means stockholder approval is not immediately required for certain share issuances related to the offering, streamlining the process.
• The ability to conduct multiple closings on a rolling basis allows for continued capital inflow over time.

Negatives

• The offering price of $5.00 per unit is significantly higher than the common stock's closing price of $1.90 on January 26, 2026, implying a substantial premium for new investors.
• Investor Warrants, with an exercise price of $4.00, are currently out-of-the-money relative to the common stock's recent trading price, requiring significant stock appreciation to become profitable.
• The Series A Preferred Stock carries no voting rights (except as required by law) and no dividends, which may be less attractive to some investors seeking immediate returns or governance influence.
• The initial closing amount of $25,450 (5,090 units at $5.00 each) is relatively small, potentially indicating a slower-than-anticipated uptake or a cautious initial tranche.

Risks

• The securities (warrants and underlying shares) have not been registered with the SEC or any state securities commission and may only be offered or sold pursuant to an exemption from registration.
• Warrant Shares acquired upon exercise may have restrictions upon resale imposed by state and federal securities laws.
• Beneficial ownership limitations (initially 4.99%, adjustable to 9.99%) restrict the number of common shares a holder can own after exercising warrants.
• Issuance of common stock upon conversion of Series A Preferred Stock or exercise of warrants may be limited if it exceeds the Exchange Cap or Ownership Cap, or if issued to officers, directors, employees, or consultants, unless requisite stockholder approval is obtained.
• Neither the Investor Units, Series A Preferred Stock, nor Investor Warrants are currently listed on any exchange or quoted in any automated dealer quotation system, limiting liquidity.
• The offering price of the Investor Units is not related to, nor may it reflect, the market price of the Common Stock after the Offering.
• Agent Unit Warrants and their underlying securities are subject to a 180-day lock-up period, restricting transferability.

Future Outlook

The company intends to conduct multiple closings for its Regulation A offering on a rolling basis. The offering will continue until the maximum amount of Investor Units is sold, or until January 5, 2027, or until the company determines to terminate it at its sole discretion.

Management Comments

• Sabrina Martucci Johnson, President and Chief Executive Officer, signed the filing on behalf of Dar Bioscience, Inc.

Industry Context

StockSavvy.ai notes that Regulation A offerings are a common mechanism for smaller public companies, particularly in the biotech sector, to raise capital from a broader investor base, including non-accredited investors, with potentially lower costs and less stringent reporting than a traditional registered offering. The combination of preferred stock and warrants is a typical structure to attract investors, offering a blend of potential upside and some downside protection through liquidation preference. The significant premium of the unit offering price over the current common stock price, coupled with out-of-the-money warrants, is characteristic of speculative investments in companies where future growth or clinical milestones are anticipated to drive substantial stock appreciation.

Comparison to Industry Standards

• The 7.25% cash commission and 3% warrant coverage for the selling agent (Digital Offering, LLC) are within the typical range for best-efforts Regulation A offerings, which often see total compensation (cash and warrants) between 7% and 10% of gross proceeds.
• The 180-day lock-up period for the Agent Unit Warrants is a standard requirement imposed by FINRA Rule 5110(e)(1) for compensation received by underwriters/selling agents in public offerings.
• The Series A Preferred Stock's lack of voting rights and dividends, combined with a liquidation preference, is a common feature in preferred stock structures designed to provide capital while limiting immediate dilution of common shareholder voting power and offering a senior claim in liquidation.
• The substantial difference between the unit offering price ($5.00) and the common stock's market price ($1.90) at the time of the initial closing, along with out-of-the-money warrants ($4.00 exercise price), suggests a valuation based on future potential rather than current market metrics, which is typical for early-stage or development-focused biotech companies.

Corporate Governance

Stakeholder Impact

• **Shareholders (Existing Common Stock):** Face potential dilution from the conversion of Series A Preferred Stock and the exercise of Investor and Agent Warrants. Their voting power could be diluted over time as new shares are issued.
• **New Investors (Units):** Acquire preferred stock with a liquidation preference, offering some downside protection, and warrants for potential upside. However, they receive no immediate voting rights or dividends and hold currently out-of-the-money warrants.
• **Company:** Gains access to capital through the Regulation A offering, enhancing financial flexibility for operations and strategic initiatives. The structure allows for ongoing capital raising.
• **Selling Agent (Digital Offering, LLC):** Benefits from cash commissions, consulting fees, expense reimbursements, and Agent Unit Warrants, providing compensation for facilitating the offering.

Next Steps

• The company plans to conduct multiple closings for the Regulation A offering on a rolling basis.
• The offering will continue until the maximum offering amount of Investor Units has been sold, or until January 5, 2027, or until the company determines to terminate the offering.
• Holders of Series A Preferred Stock have the option to convert their shares into common stock at any time after issuance.
• The company has the right to force conversion of Series A Preferred Stock under specific conditions (e.g., change in control, common stock price targets, or a qualified public offering).
• The company has a call option to redeem outstanding Series A Preferred Stock commencing on the third anniversary of the Original Issue Date.
• Investor Warrants are exercisable for 36 months from their issuance date.
• Agent Unit Warrants are exercisable for five years from the commencement of sales in the offering (January 7, 2026).
• Digital Offering, LLC may request a single demand registration right for the warrants and underlying securities after 180 days from the commencement date and the final closing of sales to investors.

Key Dates

Recommendation

The successful initial closing of the Regulation A offering provides Dar Bioscience with much-needed capital, which is a positive for its operational continuity. However, the significant premium of the unit offering price over the current common stock price, coupled with out-of-the-money warrants, suggests a highly speculative investment. While the capital raise is a necessary step, investors should maintain a 'hold' position and await further clarity on the company's use of proceeds, progress on its underlying business, and the broader market's reception to subsequent closings before making more aggressive investment decisions.

Keywords

Regulation A Offering, Series A Convertible Preferred Stock, Warrants, Capital Raise, Equity Financing, SEC Filing, DARE Bioscience, Preferred Stock Conversion, Investor Warrants, Agent Warrants